Antibiotic-Resistant Urinary Infections Strike Nearly Half of Kidney Transplant Patients in Landmark Study

Kidney transplantation offers patients with end-stage renal disease a second chance at life, but a new large-scale study reveals a formidable and growing threat to that second chance: drug-resistant urinary tract infections. Researchers at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia, followed 1,804 adult kidney transplant recipients over an eight-year period and found that nearly four in ten developed a urinary tract infection within the first year after surgery. More striking still, almost half of those infections were caused by bacteria producing extended-spectrum beta-lactamases, or ESBLs, enzymes that dismantle many of the most commonly used antibiotics in modern medicine. The findings, published in Frontiers in Transplantation, suggest that these resistant infections are not merely a treatment nuisance but an independent driver of graft failure and death.

The scale of the problem became apparent as soon as the researchers began tracking the timing of infections. Of the 693 recipients who developed a urinary tract infection during the first year, 57.4 percent were diagnosed within the first 30 days after transplantation, and 84.2 percent within the first 90 days. This concentration of infections in the earliest weeks is no coincidence. It coincides with the period of most intense immunosuppression, when the drugs that prevent the immune system from attacking the new kidney also strip away its defenses against invading microbes. It is also the window during which patients carry urinary catheters and ureteric stents, small plastic tubes surgically placed to protect the delicate connection between the transplanted kidney and the bladder.

That stent connection proved to be one of the most intriguing threads in the study. Among recipients with complete timing data, 64.3 percent experienced their first infection while the ureteric stent was still in place, compared with 35.7 percent after removal. Expressed as rates per unit of time, infections occurred at 6.77 per 1,000 patient-days during stenting versus just 0.66 per 1,000 patient-days afterward, a tenfold difference in crude terms. Yet when the researchers applied statistical adjustments for the time elapsed since transplantation, the stent itself lost its apparent culpability. The adjusted analysis showed no independent association between stent presence and infection risk, suggesting that the early post-transplant period, with its heavy immunosuppression and frequent instrumentation, is the true engine of vulnerability rather than the stent alone.

Identifying who is most at risk proved equally revealing. Using multivariable logistic regression, the team found that female sex carried the largest effect, with women facing more than four times the odds of developing a first-year infection compared with men. Older age, deceased donor transplantation, a history of urinary tract infection before the transplant, and post-transplant urological complications such as ureteric strictures and leaks all independently raised the risk. Complications involving the ureter, the tube that carries urine from the new kidney to the bladder, were especially potent, multiplying the odds of infection more than eightfold. These findings give clinicians a practical checklist for flagging high-risk recipients before infection ever takes hold.

The microbiological picture was dominated by gram-negative bacteria, with Escherichia coli and Klebsiella species leading the list, followed by Enterococcus and Pseudomonas. What set this cohort apart was the sheer proportion of resistant organisms. ESBL-producing bacteria were identified in 47.9 percent of infected recipients, with 41.4 percent already resistant at their very first infection. This figure towers over the global estimate of roughly 10 percent reported in earlier meta-analyses and exceeds even the elevated rates documented in Asia and South America. The researchers attribute this shift to regional patterns of antimicrobial resistance, underscoring how local epidemiology can transform the risk landscape for transplant patients.

Resistant infections also behaved differently from their susceptible counterparts. Patients with ESBL infections experienced significantly more recurrent episodes, with a median of three infections in the first year compared with two among those infected with non-resistant bacteria. Their infections clustered even more tightly around the stented period, occurring during stent indwelling in 69.0 percent of cases versus 60.1 percent for non-ESBL infections. And when infections did appear after stent removal, ESBL cases arrived much sooner, at a median of 25 days versus 61 days. Bloodstream invasion, measured by positive blood cultures, was also more than twice as common in the ESBL group, at 10.2 percent versus 4.5 percent, pointing to a more invasive bacterial phenotype.

The consequences for patient and graft survival were sobering. In time-updated statistical models that treated infection as an exposure beginning on the day it occurred, any urinary tract infection was associated with a 2.66-fold increase in all-cause mortality. When the researchers separated infections by resistance status, both non-ESBL and ESBL first episodes independently predicted death, with hazard ratios of 2.34 and 3.15 respectively. Death-censored graft loss, meaning the loss of kidney function from causes other than patient death, was independently associated with ESBL infection in the day-365 landmark analysis, with an adjusted hazard ratio of 2.51. Crude rates told a consistent story: recipients with infections faced higher rates of biopsy-proven rejection, graft loss, and death compared with those who remained infection-free.

The authors are careful to frame these associations with appropriate caution. Because the study is retrospective and observational, it cannot prove that infections cause graft failure or death; it is possible that urinary infections serve as markers of underlying recipient vulnerability, transplant complexity, or healthcare exposure rather than acting as direct agents of harm. Residual confounding from unmeasured factors such as prior antibiotic exposure, colonization burden, and treatment details cannot be excluded. The absolute number of graft loss events was also low, at fewer than 4 percent over three years, which limits statistical power. Nevertheless, the consistency of the mortality signal across multiple model specifications lends weight to the conclusion that early infections, whether resistant or not, carry real clinical consequences.

What emerges from this work is a clear mandate for change in transplant practice. The researchers argue for enhanced surveillance in the critical first months after surgery, region-specific antimicrobial stewardship programs that account for local resistance patterns, and optimized management of ureteric stents and other urological hardware. They also emphasize the importance of addressing modifiable risk factors, including pre-transplant urinary infections and urological complications, before patients ever reach the operating table. As ESBL-producing organisms continue their global spread, transplant centers that ignore the shifting microbial landscape may find that the very infections they once treated as routine nuisances have become decisive threats to the survival of both graft and patient.

Subject of Research: Urinary tract infections and ESBL-producing bacteria after kidney transplantation

Article Title: Early urinary tract infection after kidney transplantation: timing, stent association, extended-spectrum β-lactamase infections, and clinical outcomes in a large cohort

Article References: Nasr, R. S. F., Broering, D. C., Obeid, D. A. G., Almaghrabi, R., Hussein, E. M. M. A., Teljabini, A. N., Almadi, M. M. S., & Ali, T. Z. (2026). Early urinary tract infection after kidney transplantation: timing, stent association, extended-spectrum β-lactamase infections, and clinical outcomes in a large cohort. Frontiers in Transplantation, 5, Article 1902904. https://doi.org/10.3389/frtra.2026.1902904

Image Credits: AI Generated

DOI: 10.3389/frtra.2026.1902904

Keywords: kidney transplantation, urinary tract infection, ESBL, antimicrobial resistance, ureteric stent, graft loss, rejection, mortality, immunosuppression, Klebsiella, E. coli, transplant outcomes